A clinical trial testing vaccines designed to prevent lung cancer in people at risk of recurrent or new lung cancer

Lung cancer is a very serious illness and unfortunately, it's the most common cause of cancer death in the UK. Researchers know that lung cancer usually develops over a long time, often many years or even decades. During this time, changes happen in the cells lining the lungs, especially in people who smoke. These changes start with small faults in the cells' genetic material, like tiny alarm bells ringing. These 'alarm signals' are called neoantigens, and they are like flags telling the immune system something is wrong.

Normally, our amazing immune system spots these 'flag-waving' cells and gets rid of them. However, sometimes the immune system misses them, or doesn't react strongly enough. When this happens, these faulty cells can survive, gather more problems, and eventually grow into full-blown lung cancer. At this stage, people might notice symptoms like a cough or breathlessness, and the cancer can be seen on scans. The new vaccine being tested, called ChAdOx2 LungVax, aims to give the immune system a boost. It's designed to 'teach' the immune system to reliably spot and destroy these early faulty cells that display the 'flags,' before they can develop into cancer.

This trial is an early-stage study (Phase I), which means the main focus is on checking the vaccine's safety. However, researchers will also be looking to see if it shows signs of being effective in preventing new or returning lung cancer. They are hoping this vaccine could offer a new way to prevent this very serious disease, especially for those known to be at a higher risk.